Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)

Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)

The METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) was reported by Prof Choueiri at the European Cancer Congress 2015. This presentation follows the publication in the New England Journal of Medicine of the METEOR trial back-to-back with the CheckMate 025 trial...

Full description

Bibliographic Details
Main Author: Toni Choueiri
Format: Article
Language:English
Published: European Medical Journal 2015-11-01
Series:European Medical Journal Oncology
Subjects:
ECC
European Cancer Congress
Online Access:http://emjreviews.com/wp-content/uploads/Cabozantinib-Versus-Everolimus-in-Patients-with-Advanced-Renal-Cell-Carcinoma-Results-of-a-Randomised-Phase-III-Trial.pdf

Similar Items

Similar Items